Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.42 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410833 | 0.82 | KMT2A (0.47) | MMP7SLC22A12MEN1KMT2AALDH1A1 | |
| SCHEMBL4029025 | 0.73 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL13290746 | 0.73 | KMT2A (0.51) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL6732196 | 0.72 | SLC22A12 (0.57) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL5184840 | 0.71 | MMP7 (0.53) | MMP7SLC22A12MEN1KMT2AALDH1A1 | |
| SCHEMBL17698979 | 0.71 | SLC22A12 (0.60) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL7065567 | 0.70 | MMP7 (0.61) | MMP7SLC22A12MEN1KMT2AALDH1A1 | |
| SCHEMBL29536289 | 0.70 | SLC22A12 (0.58) | MMP7SLC22A12MEN1KMT2AALDH1A1 | |
| SCHEMBL1767681 | 0.70 | SLC22A12 (0.58) | MMP7SLC22A12MEN1KMT2AALDH1A1 | |
| SCHEMBL422146 | 0.70 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021765-A1 | FLUORINATED LANTHANIDE PROBES FOR 19F MAGNETIC RESONANCE APPLICATIONS | UNIVERSITY OF DURHAM (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2148881-A1 | FLUORINATED LANTHANIDE PROBES FOR 19F MAGNETIC RESONANCE APPLICATIONS | UNIVERSITY OF DURHAM (GB) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008132433-A1 | FLUORINATED LANTHANIDE PROBES FOR 19F MAGNETIC RESONANCE APPLICATIONS | UNIVERSITY OF DURHAM (GB) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021765-A1 | FLUORINATED LANTHANIDE PROBES FOR 19F MAGNETIC RESONANCE APPLICATIONS | SLC6A3, SLC39A3, L3MBTL3 | MMP7 2458/4885SLC22A12 621/4885MEN1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.